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Summary
Hereditary alpha-tryptasemia (HaT) is an autosomal dominant (AD) genetic trait characterized by elevated basal serum tryptase R8 ng/
mL, caused by increased a-tryptase-encoding TPSAB1 copy number. HaT affects 5% to 7% of Western populations and has been associated with joint hypermobility. Hypermobility disorders are likewise frequently AD, but genetic etiologies are often elusive. Genotyping
of individuals with hypermobility spectrum disorder (n ¼ 132), hypermobile Ehlers-Danlos syndrome (n ¼ 78), or axial skeletal abnormalities with hypermobility (n ¼ 56) was performed. Clinical features of individuals with and without HaT were compared. When
analyzing our combined cohorts, dysphagia (p ¼ 0.007) and retained primary dentition (p ¼ 0.0003) were significantly associated
with HaT, while positive associations with anaphylaxis (p ¼ 0.07) and pruritus (P ¼ 0.5) did not reach significance likely due to limited
sample size. Overall, HaT prevalence is not increased in individuals with hypermobility disorders, rather linked to a unique endotype,
demonstrating how HaT may modify clinical presentations of complex patients.

Report
Hereditary alpha-tryptasemia (HaT) is an autosomal dominant genetic trait characterized by elevated basal serum
tryptase R8 ng/mL. HaT is caused by increased a-tryptase
encoding TPSAB1 copy number on a single allele and is
common among Caucasians, affecting 5% to 7% of the
Western populations in which this has been studied.1-5 It
has been associated with symptoms suggestive of mast
cell-mediator release as well as a number of multisystem
complaints, notably certain congenital connective tissue
abnormalities including joint hypermobility, scoliosis, retained primary teeth, and less commonly, nail/patella syndrome, ankle protonation, valgus deformity, neonatal
clubbing without cardiopulmonary disease, webbed neck,
torticollis, club feet, hip dysplasia, pectus excavatum,
high arched palate, syndactyly, genus valgus, pes planus,
tibial torsion, hyperlordosis, and alveolar mandibular hypoplasia.1-4,6-9 However, these findings have largely been
reported among populations of individuals highly selected
for comorbid conditions such as these, leading to potential
referral or ascertainment biases.
In addition to studies of symptomatic individuals with
HaT, clinical studies have also described an association between symptoms of mast cell activation and connective
tissue abnormalities as well.10,11 While data are limited, it
is estimated that two-thirds of individuals with HaT may
be asymptomatic.1,3 However, two recent independent

studies have demonstrated HaT to be a major modifier of
clonal and non-clonal mast cell-associated disorders,
including systemic mastocytosis, idiopathic anaphylaxis,
and venom allergy, where individuals with HaT were 2to 3-fold more likely to present with these disorders and
to have severe mast cell-mediator symptoms including
anaphylaxis.2,5 Thus, we set out to determine whether
HaT was associated with connective tissue abnormalities
in well-characterized cohorts of individuals recruited for
connective tissue disorders and/or whether HaT modifies
clinical phenotypes or presentations of these individuals,
independent of recruitment or ascertainment biases linked
to centers specializing in mast cell-associated disorders or
syndromic presentations of allergic inflammation.
Tryptase genotyping of TPSAB1 and TPSB2 [MIM:
191801] was performed using droplet digital PCR, as
described,3 in two cohorts. The first cohort was composed
of individuals with hypermobility spectrum disorder
(HSD) and hypermobile Ehlers-Danlos syndrome (hEDS
[MIM: 130020]). These individuals were assessed by their
respective rheumatologists, allergists, and clinical geneticists to determine diagnoses. The second cohort was
composed of individuals with axial skeletal abnormalities,
namely with pediatric-onset scoliosis or Chiari malformation, who had concomitant joint hypermobility resulting
from hypermobile Ehlers-Danlos syndrome or a Beighton
score of R6. Approximately half of the second cohort
had clinical phenotypes, prompting formal medical
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Table 1.

Clinical manifestations associated with HaT among individuals with joint hypermobility disorders
HSD and hEDS

HSD, hEDS, and axial skeletal abnormality with
hypermobility

HaT
no HaT
(n ¼ 9) (n ¼ 201)

HaT
no HaT
(n ¼ 11) (n ¼ 225)

Manifestation

n (%)

n (%)

OR (95% Cl) RR (95%Cl)

p value n (%)

Anaphylaxis

1 (11)

5 (3)

4.8 (0.4–32.5) 4.47 (0.7–23.1) 0.2

2 (18)

n (%)

OR

RR

p value

8 (4)

5.9 (1.1–26.4) 5.0 (1.3–17.1) 0.07

Pruritus

4 (57)

45 (42)

1.8 (0.5–7.4) 1.3 (0.6–2.2)

0.5

5 (56)

51 (39)

1.9 (0.5–6.5)

1.4 (0.7–2.3)

0.5

Inflammatory
bowel disease

0 (0)

2 (1)

0 (0.0–49.1)

>0.99

0 (0)

3 (1)

0 (0.0–24.1)

0 (0.0–22.2)

>0.99

IBS-like symptoms

4 (44)

31 (26)

2.2 (0.7–8.2) 1.7 (0.7–3.2)

0.3

–

–

–

–

–

Gastroesophageal
reflux

7 (78)

134 (69)

1.6 (0.3–7.8) 1.1 (0.7–1.4)

0.7

–

–

–

–

–

Retained primary
dentition*

3 (33)

1 (1)

96
64.3
(11.6–1,240) (9.6–416)

0.0002 3 (27)

1 (0)

81
(10.2–1,048)

59.2
(8.7–387.8)

0.0003

101 (52)

1.9 (0.5–7.0) 1.3 (0.7–1.8)

0.5

–

–

–

–

–

0.2

–

–

–

–

–

1.1 (0.6–1.3)

0.7

Generalized joint
6 (67)
hypermobility (BS R 5/9)

0 (0.0–36.7)

Tilt-table test

2 (100) 37 (47)

R0.5

Headache
and/or migraine

6 (67)

127 (69)

0.9 (0.2–3.4) 1.0 (0.5–1.3)

>0.99

8 (73)

146 (70)

1.1 (0.3–4.1)

Sleep disturbances

7 (88)

106 (85)

1.2 (0.2–14.1) 1 (0.6–1.2)

>0.99

9 (90)

116 (78)

2.5 (0.4–28.0) 1.1 (0.8–1.3)

Dysphagia*

7 (78)

56 (32)

7.3 (1.5–35.4) 2.4 (1.4–3.3)

0.009

8 (73)

61 (31)

5.9 (1.7–21.1) 2.3 (1.4–3.3)

0.007

Clubfeet

0 (0)

6 (3)

0 (0.0–13.5)

0 (0.0–11.3)

>0.99

–

–

–

–

Chronic fatigue

9 (100) 178 (91)

R0.2

1.1 (0.8–1.2)

>0.99

10 (91)

193 (88)

1.4 (0.2–15.7) 1.0 (0.7–1.2)

>0.99

Neurological bladder

0 (0)

0 (0.0–23.29) 0 (0.0–15.9)

>0.99

0 (0)

5 (2)

0 (0.7–1.0)

>0.99

5 (3)

2.1 (0.7–2.8)

–

0 (0.0–14.7)

0.06

BS, Beighton score; HaT, hereditary alpha-tryptasemia; hEDS, hypermobile Ehlers-Danlos syndrome; HSD, hypermobility spectrum disorder; IBS, irritable bowel
syndrome; OR, odds ratio; RR, relative risk; 95% Cl, 95% confidence limits; –, indicates unavailable datapoints.
*Retained primary dentition and Dysphagia rows indicate statistically significant associations.

genetic evaluations; none of these individuals were found
to have a molecular genetic diagnosis for their clinical presentation(s). Among individuals with HSD only, 3.8% (5 of
132) were found to have HaT (Table S1). Similarly, 5.1% (4
of 78) of individuals diagnosed with hEDS and 7% (4 of 56)
of those with axial skeletal abnormalities and hypermobility were found to have HaT. Thus, as a combined cohort,
the prevalence of HaT was 4.9% (13 of 266), comparable to
the prevalence established in unselected individuals
(4.4%–7.5%),1,2,4,5 indicating that HaT is not associated
with these heritable connective tissue disorders.
In order to determine whether HaT might modify clinical phenotypes among individuals with joint hypermobility in a manner similar to that reported among patients
with venom allergy, idiopathic anaphylaxis, and mastocytosis,2,5 both cohorts were queried retrospectively via chart
review or phone interview. Prevalence of clinical phenotypes previously associated with HaT3 were subsequently
compared based on the presence or absence of HaT (Table
1, Table S1).
Among individuals with hEDS, HaT was associated with
an increased prevalence of retained primary dentition
requiring surgical extraction (odds ratio [OR] R 4.8; p ¼
0.05). Among individuals with HSD, HaT was associated
with an increased prevalence of retained primary dentition
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(OR 79.3 [6.5–1,140]; p ¼ 0.004) and dysphagia diagnosed
by barium swallow or manometry (OR 0.2 [0.01–0.6]; p ¼
0.02) when compared with those without HaT. No significant differences were identified based on the presence of
HaT when examining our second cohort of individuals
with axial skeletal abnormalities alone (Table S1), though
non-significant positive associations were observed with
anaphylaxis, pruritus, and dysphagia. It should be noted
that of the 56 people genotyped in this second cohort,
clinical manifestations were available for only 26 of them
(n ¼ 2/4 with HaT and n ¼ 25/52 without HaT). When individuals with hEDS and HSD were combined as a single
cohort, dysphagia (OR 7.3 [1.5–35.4]; p ¼ 0.009) and retained primary dentition (OR 96 [11.6–1,240]; p ¼
0.0002) remained significantly associated with HaT (Table
1). After correcting for multiple comparisons, associations
between HaT and retained primary dentition (adjusted p ¼
0.0028) in the combined hEDS/HSD cohort, remained statistically significant. When combining genotyped individuals with hEDS, HSD, and axial skeletal abnormalities (n ¼
236) (Table 1), the prevalence of retained primary dentition (p ¼ 0.0003, adjusted p ¼ 0.004) and dysphagia (p ¼
0.007, adjusted p ¼ 0.098) remained significantly
increased, although only the former did when accounting
for multiple comparisons.
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An increased prevalence of HaT was not observed in
either cohort of HSD/hEDS patients or those with axial
skeletal abnormalities and joint hypermobility, where genotyping could be performed. However, as has been reported in other acquired genetic conditions,2,5 we found
that HaT was associated with a unique endotype, either
due to independent association or modification of certain
characteristics or clinical features in these individuals.
Interestingly, the only connective tissue abnormality
found previously to be significantly associated with HaT
among unselected healthy adults was retained primary
dentition.3
Whether HaT may cause clinical manifestations or
modify the symptomatic presentation of other clinical disorders remains a matter of scientific debate. However, the
associations seen here between HaT and retained primary
dentition remained statistically significant after correcting
for multiple comparisons, and are remarkably consistent
with prior associations reported in both selected and unselected populations.2-7,12,13 Interestingly, there was also an
increased prevalence of anaphylaxis and pruritus among
individuals with joint hypermobility and HaT, phenotypes
also strongly linked to HaT in previous studies2,3,5,7; however, the sample size was limited, and these did not reach
statistical significance when adjusting for multiple comparisons (OR 5.9 [1.1–26.0]; p ¼ 0.07, adjusted p ¼ 0.98)
and (OR 1.9 [-0.5–6.5]; p ¼ 0.5, adjusted p >0.99),
respectively.
While additional mechanistic work is ongoing to understand the phenotypes linked to HaT, these current data
indicate that HaT is not associated with congenital joint
hypermobility disorders. Additional larger studies would
help confirm these findings in the future. However, given
that HaT is common, it may frequently be present among
individuals with such connective tissue abnormalities
where it may modify and add to the diverse clinical presentations of these uniquely complex patients.
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Supplemental materials and methods
Subjects with hEDS and HSD
Informed consent was provided on an IRB-approved research protocol, IRB number: NP3873 Study of
TPSAB1 gene copy number in a cohort of patients with hypermobile Ehlers-Danlos syndrome (hEDS)
and Hypermobility Spectrum Disorders (HSD) was approved by the local Ethical Committee (Comitato
Etico di Brescia, ASST degli Spedali Civili, Brescia, Italia) under Prof. Marina Colombi. Individuals were
evaluated in a tertiary Italian referral center for the diagnosis and management of HDCT at the Spedali
Civili University Hospital of Brescia. Personal medical histories were obtained, and complete physical
examinations were performed to screen and diagnose individuals with hEDS according to the 2017
criteria (1). People with symptomatic syndromic joint hypermobility but not fulfilling the new
diagnostic criteria for hEDS were classified as having HSD (2). A small subset also underwent clinically
indicated Tilt-table testing for symptoms suggestive of autonomic dysfunction.
All clinical phenotypes reported in this paper - and most pertinently connective tissue phenotypes were ascertained by clinical geneticists and/or neurologists specializing in these disorders, and their
teams, prior to tryptase genotyping.

Subjects with axial skeletal abnormality and hypermobility
Informed consent was obtained on a Washington University IRB-approved research protocol (IRB ID
#201102118). Subjects were recruited from cohorts of people with scoliosis or Chiari malformation.
They were selected due to a concomitant clinical diagnosis of classical EDS or a Beighton score of ≥6. A
subset of individuals (N=26) was available from which clinical symptoms could be queried.

Tryptase genotyping
Genotyping of TPSAB1 and TPSB2 was performed as previously described (3). In short, droplet-digital
PCR was performed from extracted genomic DNA on a QX200 (Bio-Rad, Hercules, CA) using a manual
2

droplet generator and custom primer/probe sets for α- and β-tryptase sequences at TPSAB1 and TPSB2
employing the reference probe AP3B1 (Bio-Rad). Primary results can be provided by the author upon
request.

Statistical Analyses
Fisher’s exact test was used where appropriate. For comparisons reaching statistical significance, a
Bonferroni correction for multiple comparisons was applied to test the strength of association.
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Table S1. Clinical manifestations associated with HaT among individuals with joint hypermobility disorders.
HSD

hEDS

HaT
(N=5)

no HaT
(N=127)

Manifestation

N (%)

N (%)

OR (95%Cl)

RR (95%Cl)

anaphylaxis

1 (20)

1 (0.8)

31 (1.3-582.9)

pvalue
0.08

pruritus

3 (100)

26 (38)

-

24.8 (2.65207.3)
2.6 (1.1-3.6)

inflammatory bowel
disease
IBS-like symptoms

0 (0)

2 (2)

0.0 (0.0-60)

0 (0.0-37.4)

3 (60)

15 (19)

6.4 (1.2-37.4)

3.2 (1.1-6.2)

0.06

gastroesophageal reflux

4 (80)

74 (61)

2.6 (0.4-32.3)

1.3 (0.6-1.7)

0.6

retained primary
dentition
generalized joint
hypermobility (BS≥5/9)
tilt-table test

2 (40)

1 (0.8)

48 (6.6320.4)
1.6 (0.5-3.5)

0.004

0.06

2 (40)

30 (25)

1 (100)

18 (75)

-

1.3 (0.3-1.8)

>0.99

4 (80)

71 (62)

2.4 (0.4-30.3)

1.3 (0.6-1.7)

0.7

0.6

headache and/or
migraine
sleep disturbances

4 (100)

59 (82)

-

dysphagia

4 (80)

27 (25)

0.2 (0.01-0.6)

3.2 (1.4-4.9)

0.02

clubfeet

0 (0)

5 (4)

0.0 (0.0-25.2)

0.0 (0.0-13.6)

>0.99

chronic fatigue

5 (100)

106 (86)

-

1.2 (0.7-1.3)

>0.99

neurological bladder

0 (0)

4 (3)

0.0 (0.0-32)

0.0 (0.0-19.6)

no HaT
(N=74)

N (%)

N (%)

OR (95%Cl)

RR (95%Cl)

0 (0)

4 (5)

0.0 (0.0-19.0)

0.0 (0.0-11.9)

1 (25)

19 (50)

0.3 (0.02-2.5)

0.5 (0.09-1.5)

0 (0)

0 (0)

-

-

1 (25)

16 (41)

0.5 (0.03-3.5)

0.6 (0.1-1.9)

>0.99

3 (75)

60 (82)

0.7 (0.09-9.0)

0.9 (0.4-1.2)

0.6

1 (25)
4
(100)
1
(100)

0 (0)

>4.8

>2

71 (96)

>0.04

1.0 (0.5-1.1)

19 (35)

>0.2

2.9 (0.6-4.3)

2 (50)

56 (80)

0.3 (0.04-1.7)

0.6 (0.2-1.1)

3 (75)

47 (90)

0.3 (0.04-4.9)

0.8 (0.9-3.0)

3 (75)

29 (44)

1.7 (0.7-2.6)

0 (0)
4
(100)

1 (1)

3.8 (0.5-50.9)
0.0 (0.0166.5)

0.0 (0.0-59.3)

72 (99)

>0.006

1.0 (0.5-1.1)

0 (0)

1 (2)

0.0 (0.0-204)

0.0 (0.0-68.8)

>0.99

79.3 (6.51140)
2.0 (0.3-10.3)

1.2 (0.6-1.4)

axial skeletal abnormality with hypermobility

HaT
(N=4)

>0.99

>0.99

HaT
(N=2)

no HaT
(N=24)

N (%)

N (%)

OR (95%Cl)

RR (95%Cl)

1 (50)

3 (13)

7 (0.3-137.3)

4 (0.6-15.8)

pvalue
0.3

1 (50)

6 (25)

3 (0.1-59.6)

2 (0.3-5.9)

0.5

0 (0)

1(4)

0 (0.0-108.0)

0 (0.0-32.9)

>0.99

0 (0)

0 (0)

-

-

>0.99

2 (100)

19 (79)

≥ 0.1

1.3 (0.4-1.7)

>0.99

0.4

2 (100)

10 (42)

≥ 0.6

2.4 (0.8-4.1)

0.2

0.3

1 (50)

5 (21)

3.8 (0.2-75.2)

2.4 (0.4-7.6)

0.4

1 (50)

15 (63)

0.6 (0.0-12.6)

0.8 (0.1-1.7)

>0.99

0

0 (0)

-

-

>0.99

pvalue
>0.99
0.6
>0.99

0.05
>0.99
0.4
0.2

>0.99
>0.99
>0.99

HSD - hypermobility spectrum disorder; hEDS - hypermobile Ehlers-Danlos syndrome; HaT - hereditary alpha-tryptasemia; BS - Beighton score. OR - Odds Ratio; RR – Relative Risk; 95% Cl- 95% Confidence limits; For OR or RR where the exact
value could not be determined, values are indicated as the ≥ the lower limit of the 95% CI; bold typeface indicates statistically significant associations; grey areas indicate unavailable datapoints.
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